Breastmilk: Research Shows It Can Destroy Cancer Cells!

by Donna Walls, RN, BSN, IBCLC, ANLC

Years ago, maybe 20 or so, I went to a conference session entitled “Breastmilk Apoptosis.” I had no idea what that meant, but a Swedish researcher explained how his team was applying breastmilk to cancer cells in a petri dish and found the milk was actually destroying malignant cells. I was astounded- this breastmilk is really great stuff! But years went by and I didn’t hear about “apoptosis” again, until just recently.

Through the years, I have talked with some patients who were using breastmilk during cancer treatments and even heard a bit about milk banks having cancer therapy on their list of uses, but you would have thought if breastmilk was really killing cancer cells it would have been the lead story on the evening news.

Fast forward to 2019 and there are some research articles surfacing touting the ability of breastmilk to actually destroy cancer cells. Substances found only in breastmilk, alpha-lactalbumin, combined with fatty acids (most commonly oleic acid) have the capability of destroying malignant tumor cells. (Hakansson et al., 1995; Reed, 2003)

This early breastmilk research began looking at the mechanisms of breastmilk in killing pathogenic germs. They were using cancer cells, as they commonly do with experiments, and were surprised to find the cancer cells being destroyed. They then applied the breastmilk to healthy cells and found no negative effects to healthy cells.

In 1995, Professor Catharina Svanborg of the Lund University in Sweden was working on the application of breastmilk components to cancer cells stated, “We have very strong data in mice showing dose-dependent reduction of the tumor, to the point of disappearance. And we have laboratory evidence for effects against many different types of cancer cells and it is therapeutic use in animal models of brain tumors and colon cancer as well as bladder cancer.”

In another trial study carried out in 2007 by Motol University Hospital in Prague and overseen by scientists from Lund University in Sweden, 8 out of the 9 patients in the study were found to be passing tumor cells in their urine just two hours after being given an alpha-lactalbumin complex synthesized drug resulting in decreased tumor size. In another early trial involving 40 patients with hard-to-treat bladder cancer it was found that all 20 who were given a drug based on the alpha-lactalbumin complex had whole tumor fragments in their urine.

This complex of alpha-lactalbumin and fatty acids is referred to as HAMLET (human alpha-lactalbumin made lethal to tumor cells). This complex induces apoptosis which is defined as cell death, cell suicide or programmed cell death. HAMLET has been shown to induce anti-tumor effects on more than 40 different lymphomas and carcinomas. Also, these cells were able to distinguish between malignant cells and normally functioning cells and does not exert their anti-tumor effects on healthy cells. (Delgado Y. 2015)

So, what are the practical aspects of using breastmilk as a treatment for cancer? Synthesis of the HAMLET cell complex is being used in research studies and the development of anti-cancer medications by the pharmaceutical industry “looks promising”.  FDA approval of clinical trials included the statement “the unique characteristic of the protein could potentially help battle cancer in adults, some doctors say”. (Delgado Y.)

Dr. Lori Feldman-Winter at Cooper University Hospital in New Jersey stated, “There’s promising research that would indicate that in the future the solution for not only preventing cancer, but even treating and curing cancer might be in human milk.”

If, in time, breastmilk, or synthesized HAMLET cells, would become a routine part of cancer treatment there could be a concern about the availability of human milk. “In the past we have had one to two inquiries a month,” said Dr. Deborah Tuttle of the Mothers’ Milk Bank at Christiana Hospital in Newark, Delaware. Human milk banks have only a limited supply of human milk with premature and vulnerable infants as the priority for the limited amount of human milk available.

There is also a concern that adult cancer patients, out of desperation, might seek sources of breastmilk that provide unsafe products claiming to have benefits as cancer therapies. We  know that breastfeeding reduces the risk of many cancers in infants as well as reducing the risk of breast and ovarian cancer in breastfeeding mothers. There are many benefits of using human milk, and with this research, another promising treatment for cancer without the side effects of current treatments can be added to the list.

References

Rath EM, Cheng YY, Pinese M, Sarun KH, Hudson AL, Weir C, Wang YD, Håkansson AP, Howell VM, Liu GJ, et al BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state. PLoS One. 2018; 13(8):e0203003. Epub 2018 Aug 29.

Ho JCS, Nadeem A, Svanborg C. HAMLET – A protein-lipid complex with broad tumoricidal activity.Biochem Biophys Res Commun. 2017 Jan 15;482(3):454-458. doi: 10.1016/j.bbrc.2016.10.092. Epub 2017 Feb 3. Review.PMID:28212731.

Rath EM, Duff AP, Håkansson AP, Vacher CS, Liu GJ, Knott RB, Church WB. Structure and Potential Cellular Targets of HAMLET-like Anti-Cancer Compounds made from Milk Components. J Pharm Pharm Sci. 2015;18(4):773-824. Review. PMID:26626257

Aits S, Gustafsson L, Hallgren O, Brest P, Gustafsson M, Trulsson M, et al. HAMLET (human alpha-lactalbumin made lethal to tumor cells) triggers autophagic tumor cell death. Int J Cancer. 2009; 124:1008–1019. 10.1002/ijc.24076 [

Fontana A, Spolaore B, Polverino de Laureto P. The biological activities of protein/oleic acid complexes reside in the fatty acid. Biochim Biophys Acta. 2013 Jun;1834(6):1125-43. doi: 10.1016/j.bbapap.2013.02.041. Epub 2013 Mar 14. Review PMID:23499846.

Brinkmann CR, Thiel S, Otzen DE. Protein-fatty acid complexes: biochemistry, biophysics and function. FEBS J. 2013 Apr;280(8):1733-49. doi: 10.1111/febs.12204. Epub 2013 Mar 18. Review.PMID:23441831

Mok KH, Pettersson J, Orrenius S, Svanborg C. HAMLET, protein folding, and tumor cell death.

Biochem Biophys Res Commun. 2007 Mar 2;354(1):1-7. Epub 2006 Dec 29. PMID:17223074

Svensson M, Düringer C, Hallgren O, Mossberg AK, Håkansson A, Linse S, Svanborg C.

Hamlet–a complex from human milk that induces apoptosis in tumor cells but spares healthy cells. Adv Exp Med Biol. 2002;503:125-32. PMID:12026011

Svensson, M, Håkansson, A, Mossberg, A‐K, Linse, S & Svanborg, C ( 2000) Conversion of α‐lactalbumin to a protein inducing apoptosis. Proc Natl Acad Sci USA 97, 4221– 4226.

Mossberg, A‐K, Hou, Y, Svensson, M, Holmqvist, B & Svanborg, C ( 2010) HAMLET treatment delays bladder cancer development. J Urol 183, 1590– 1597.

Hakansson, A, Zhivotovsky, B, Orrenius, S, Sabharwal, H & Svanborg, C ( 1995) Apoptosis induced by a human milk protein. Proc Natl Acad Sci USA 92, 8064– 8068.

Hill DR, Newburg DS. Clinical applications of bioactive milk components. Nutr Rev. 2015 Jul; 73(7):463-76.

Delgado Y, Morales-Cruz M, Figueroa CM, Hernández-Román J, Hernández G, Griebenow K. FEBS The cytotoxicity of BAMLET complexes is due to oleic acid and independent of the α-lactalbumin component Open Bio. 2015; 5:397-404. Epub 2015 May 4.

Gao Z, Wang R, Qin ZX, Dong A, Liu CB. Libyan J Med. 2018 Protective effect of breastfeeding against childhood leukemia in Zhejiang Province, P. R. China: a retrospective case-control study. Dec; 13(1):1508273.

Mossberg AK, Hun Mok K, Morozova-Roche LA, Svanborg C.FEBS J. 2010 Structure and function of human α-lactalbumin made lethal to tumor cells (HAMLET)-type complexes Nov; 277(22):4614-25.

Ho C S J, Rydström A, Trulsson M, Bålfors J, Storm P, Puthia M, Nadeem A, Svanborg C.

HAMLET: functional properties and therapeutic potential. Future Oncol. 2012 Oct;8(10):1301-13. doi: 10.2217/fon.12.122. Review. PMID:23130929

Hallgren O1Aits SBrest PGustafsson LMossberg AKWullt BSvanborg C. Apoptosis and tumor cell death in response to HAMLET (human alpha-lactalbumin made lethal to tumor cells). Adv Exp Med Biol. 2008;606:217-40. doi: 10.1007/978-0-387-74087-4_8.